Hybridoma technology: is it still useful?

Moraes, Jane Zveiter de; Hamaguchi, Bárbara; Braggion, Camila; Speciale, Enzo Reina; Cesar, Fernanda Beatriz Viana; Soares, Gabriela de Fátima da Silva; Osaki, Juliana Harumi; Pereira, Tauane Mathias; Aguiar, Rodrigo Barbosa de

doi:10.1016/j.crimmu.2021.03.002

Cited by 27 publications

(25 citation statements)

References 102 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…16 However, the traditional antibodies have limitations including the unstable quality of pAbs caused by the batch-tobatch variation of immunized animals or the specificity loss of mAbs during thawing of hybridoma when it expressed additional functional variable regions. 17 Therefore, a novel type of antibody with more excellent characteristics would be urgently demanded.…”

Section: ■ Introductionmentioning

confidence: 99%

Detection of Acrylamide in Foodstuffs by Nanobody-Based Immunoassays

Liang

Zeng

Luo

et al. 2022

J. Agric. Food Chem.

View full text Add to dashboard Cite

Acrylamide is toxic aliphatic amide formed via the Maillard reaction between asparagine and reducing sugars during thermal processing of food. Herein, a specific nanobody termed Nb-7E against the acrylamide derivative xanthyl acrylamide (XAA) was isolated from an immunized phage display library and confirmed to be able to detect acrylamide. First, an indirect competitive enzyme-linked immunosorbent assay (ic-ELISA) was established for acrylamide with a limit of detection (LOD) of 0.089 μg/mL and working range from 0.23 to 5.6 μg/mL. Furthermore, an enhanced electrochemical immunoassay (ECIA) was developed based on the optimized reaction conditions. The LOD was as low as 0.033 μg/mL, threefold improved compared to that of ic-ELISA, and a wider linear detection range from 0.39 to 50.0 μg/mL was achieved. The average recoveries ranged from 88.29 to 111.76% in spiked baked biscuits and potato crisps. Finally, the analytical performance of the ECIA was validated by standard ultraperformance liquid chromatography tandem mass spectrometry (UPLC-MS/MS).

show abstract

Section: ■ Introductionmentioning

confidence: 99%

Detection of Acrylamide in Foodstuffs by Nanobody-Based Immunoassays

Liang

Zeng

Luo

et al. 2022

J. Agric. Food Chem.

View full text Add to dashboard Cite

show abstract

“…Despite the advent of many in vitro display technologies, the development of mAbs also relies on ex vivo single B cell interrogation (Box 1) [22,110]. Among the plethora of techniques enabling this process, the hybridoma technology is still used in new discovery pipelines because it is easy, cheap, and familiar to many scientists (Table 1).…”

Section: Discussionmentioning

confidence: 99%

“…Newer protocols accommodate several improvements, including some additional tissue culture measures such as the addition of cytokines and peritoneal macrophages to remove dead cells [20]. Some protocols also attempt to go beyond the PEG-based cell fusion step, implementing either electrofusion-based systems, or making use of fusogenic viruses such as Sendai virus or vesicular stomatitis virus to potentially increase the fusion efficiency between ASCs and myeloma cells, which represents one of the most relevant downsides of generating hybridomas [17,21,22].…”

Section: Glossarymentioning

confidence: 99%

Single B cell technologies for monoclonal antibody discovery

Pedrioli

Oxenius

2021

Trends in Immunology

View full text Add to dashboard Cite

“…Monoclonal antibody therapy has added great therapeutic value and enhanced the treatment efficacy for many diseases including cancer ( 106 ), infectious disease ( 107 ) and immunosuppression ( 108 ) in recent years. The credit to this success undeniably goes to the advances in technology such as hybridoma and phage display technology ( 109 ). The generated therapeutic monoclonal antibody is able to perform similar effector mechanisms as a typical human antibody which includes neutralization, activation of the complement cascade, antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent phagocytosis (ADP) ( 110 ).…”

Section: Antibody Therapymentioning

confidence: 99%

The COVID-19/Tuberculosis Syndemic and Potential Antibody Therapy for TB Based on the Lessons Learnt From the Pandemic

et al. 2022

View full text Add to dashboard Cite

2020 will be marked in history for the dreadful implications of the COVID-19 pandemic that shook the world globally. The pandemic has reshaped the normality of life and affected mankind in the aspects of mental and physical health, financial, economy, growth, and development. The focus shift to COVID-19 has indirectly impacted an existing air-borne disease, Tuberculosis. In addition to the decrease in TB diagnosis, the emergence of the TB/COVID-19 syndemic and its serious implications (possible reactivation of latent TB post-COVID-19, aggravation of an existing active TB condition, or escalation of the severity of a COVID-19 during TB-COVID-19 coinfection), serve as primary reasons to equally prioritize TB. On a different note, the valuable lessons learnt for the COVID-19 pandemic provide useful knowledge for enhancing TB diagnostics and therapeutics. In this review, the crucial need to focus on TB amid the COVID-19 pandemic has been discussed. Besides, a general comparison between COVID-19 and TB in the aspects of pathogenesis, diagnostics, symptoms, and treatment options with importance given to antibody therapy were presented. Lastly, the lessons learnt from the COVID-19 pandemic and how it is applicable to enhance the antibody-based immunotherapy for TB have been presented.

show abstract

Hybridoma technology: is it still useful?

Cited by 27 publications

References 102 publications

Detection of Acrylamide in Foodstuffs by Nanobody-Based Immunoassays

Detection of Acrylamide in Foodstuffs by Nanobody-Based Immunoassays

Single B cell technologies for monoclonal antibody discovery

The COVID-19/Tuberculosis Syndemic and Potential Antibody Therapy for TB Based on the Lessons Learnt From the Pandemic

Contact Info

Product

Resources

About